Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions

Authors

Amy E DeZern, Sidney Kimmel Cancer Center
Robert S Fulton, Washington University School of Medicine in St. Louis
Matthew J Walter, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

7-25-2023

Volume

7

Issue

14

First Page

3749

Last Page

3759

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2022008578

Rights and Permissions

DeZern AE, Goll JB, Lindsley RC, Bejar R, Wilson SH, Hebert D, Deeg J, Zhang L, Gore S, Al Baghdadi T, Maciejewski J, Liu J, Padron E, Komrojki R, Saber W, Abel G, Kroft SH, Harrington A, Grimes T, Reed H, Fulton RS, DiFronzo NL, Gillis N, Sekeres MA, Walter MJ. Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions. Blood Adv. 2023 Jul 25;7(14):3749-3759. doi: 10.1182/bloodadvances.2022008578. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution.

Recommended Citation

DeZern, Amy E; Fulton, Robert S; Walter, Matthew J; and et al., "Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions." Blood Advances. 7, 14. 3749 - 3759. (2023).
https://digitalcommons.wustl.edu/oa_4/2205

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.